ABVC BIOPHARMA, INC. (ABVC) Form 8-K — Nov 2, 2026
$ABVCForm 8-KItems 1.01, 1.02, 2.03, 3.02, 5.07, 7.01, 9.01Filed Nov 2, 2026, 9:51 AM ET0001213900-26-114729Original filing
ABVC BioPharma closed a private placement on October 30, 2026, selling senior convertible promissory notes with $4,106,060 aggregate principal for $3,387,500 in cash — a 17.5% original issue discount.
Key figures
- Debt Amount
- 4106060
- Interest Rate
- 17.5% original issue discount; 10% default interest
- Maturity Date
- 2027-06-30
- Gross Proceeds
- 3387500
- Floor price
- $0.20
- Exchange cap
- 19.99% of shares outstanding pending stockholder approval
- Conversion price
- 85% of average of 3 prior VWAPs
- Prepayment premium
- 102.5% of principal
- Placement agent fee
- 237125
- Lind warrant increase
- 20%
- Required share reserve
- 20530304
- Placement agent expenses
- 65000
- Shareholder vote approval
- 93.08% for issuance of up to 1,600,653 shares at >= $1.00
- Settlement payment to lind
- 625000
- Lind warrant original shares
- 398000
- Mandatory prepayment from financing
- lesser of 20% of net proceeds and outstanding principal
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.